Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.
Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.
Penumbra, Inc. (NYSE: PEN) has launched its advanced Indigo Aspiration System technologies, Lightning 7 and Lightning 12, in Europe following CE Mark approval. These systems, focused on mechanical thrombectomy for removing blood clots in a single session, aim to enhance patient outcomes by differentiating between clot and blood to minimize blood loss. Physicians in Europe now have access to this innovative technology, which has already shown success in the U.S. market, potentially reducing ICU stays and improving care efficiency.
Penumbra, Inc. (NYSE: PEN) will host a conference call on May 3, 2022, at 4:30 PM ET to discuss its first-quarter 2022 financial results. A press release detailing these results will be issued after market close that day. Investors can access the call through a phone line or via a webcast on the company's website. Penumbra focuses on innovative healthcare solutions and operates in over 100 countries, creating products that address significant medical needs.
Penumbra, Inc. (NYSE: PEN) has launched the REAL Immersive System y-Series, expanding its virtual reality healthcare platform. This new offering enhances patient care with upgraded hardware and a broader activity library for rehabilitation therapy. The platform now addresses conditions affecting over 50 million patients in the U.S. The improved interface, TherapyView™, allows clinicians to customize therapy programs, engaging patients more effectively. The y-Series was showcased at the American Occupational Therapy Association Annual Conference in San Antonio, TX.
Penumbra, Inc. (NYSE: PEN) is set to present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:00 PM ET. The event will showcase Penumbra's innovative therapies and its commitment to addressing challenging medical conditions.
Investors can access the presentation via a webcast on the company's website, available for two weeks post-event. Penumbra operates globally, supporting healthcare providers in over 100 countries with a robust portfolio aimed at significant unmet medical needs.
Penumbra, Inc. (NYSE: PEN) reported financial results for Q4 and full year 2021, with Q4 revenue reaching $204.0 million, a 22.2% increase from Q4 2020. Full year revenue totaled $747.6 million, up 32.6% year-over-year. US revenue represented 71% of total revenue, with vascular products growing 30.4% to $113.6 million in Q4. Despite higher operating expenses, non-GAAP operating income was $2.5 million for Q4. The company forecasts 2022 revenue between $860 million and $875 million, indicating 15% to 17% growth.
Penumbra, Inc. (NYSE: PEN) is set to present at Citi's 2022 Virtual Healthcare Conference on February 24, 2022, at 1:15 PM ET.
Investors can access the presentation via a webcast on the company's website, which will remain available for at least two weeks after the event. Penumbra, headquartered in Alameda, California, specializes in innovative healthcare therapies and serves clients in over 100 countries. For further details, visit www.penumbrainc.com.
Penumbra, Inc. (NYSE: PEN) has announced a conference call to discuss its financial results for the fourth quarter and full year of 2021. The call is scheduled for February 22, 2022, at 4:30 PM Eastern Time, following a press release detailing the financial results. This event will be accessible via phone and webcast, with the latter available on the company's website for two weeks post-call.
Penumbra focuses on innovative therapies and has a global presence, supporting healthcare providers across more than 100 countries.
Penumbra, Inc. (NYSE: PEN) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022. The management team will present at 11:15 AM ET (8:15 AM PT). Interested investors can access an audio webcast of the presentation through the company's website, available for at least two weeks post-event. Penumbra is dedicated to innovative healthcare solutions, serving providers in over 100 countries.
Penumbra, Inc. (NYSE: PEN) announced positive results from the CHEETAH clinical study of its CAT RX Catheter at the TCT conference. The study achieved high rates of blood clot removal and restored blood flow in patients with high thrombus burden. Key findings included a 99.5% reduction in TIMI thrombus grade and 97.5% of patients achieving TIMI flow grade 3 post-treatment. No serious device-related adverse events were reported. The study emphasizes the effectiveness and safety of continuous powered aspiration thrombectomy in acute coronary syndrome interventions.
Penumbra, Inc. (NYSE: PEN) reported strong financial results for Q3 2021, with a revenue increase of 25.8% year-over-year, reaching $190.1 million. Vascular product sales surged 40.3% to $105.5 million, while neuro products rose 11.5% to $84.7 million. Gross profit improved to 63.1% of total revenue, totaling $119.9 million. Operating income shifted to $8.8 million from a loss of $20.2 million a year earlier. The company also raised its 2021 revenue guidance to between $735 million to $740 million, reflecting a growth of 31% to 32% over 2020.